Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 6/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | PER2 | O15055 | 1/20 | 0.33 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.33 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11580208 | 0.87 | TAS2R14 (0.38) | TAS2R14MMP3CA12CA1CA2 | |
| SCHEMBL11434836 | 0.85 | MEN1 (0.38) | TAS2R14MMP3LMNAALDH1A1NPSR1 | |
| Hydrochloric Acid SCHEMBL11448476 | 0.84 | TAS2R14 (0.36) | TAS2R14MMP3CA12CA1CA2 | |
| SCHEMBL15524312 | 0.81 | TSHR (0.32) | ALDH1A1TSHR | |
| Methane SCHEMBL11143696 | 0.79 | TDP1 (0.30) | TSHR | |
| Ethane SCHEMBL11137426 | 0.79 | TDP1 (0.30) | TSHR | |
| SCHEMBL11392357 | 0.76 | CA12 (0.36) | TAS2R14MMP3CA12CA1CA2 | |
| SCHEMBL10312295 | 0.74 | PER2 (0.45) | TAS2R14MMP3CA12CA1CA2 | |
| Sulfuric Acid SCHEMBL28055426 | 0.74 | CA1 (0.44) | TAS2R14CA12CA1CA2CA9 | |
| SCHEMBL3792283 | 0.72 | TAS2R14 (0.37) | TAS2R14MMP3CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6225347-B1 | FOR LOWERING BLOOD PRESSURE, INHIBITING PLATELET AGGREGATION, FOR LUTEOLYTIC EFFECT, HEALING ULCER, INHIBITING GASTRIC ACID SECRETION, AS CYTOPROTECTIVE AGENT | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-05-01 | — | — | US | claimed |
| US-5891910-A | 9-halogen-(Z) prostaglandin derivatives, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-04-06 | — | — | US | claimed |
| US-11916195-B2 | Electrolyte solution, electrochemical device, lithium ion secondary battery, and module | DAIKIN INDUSTRIES, LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-20230387465-A1 | COMPOUND, COMPOSITION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY AND MODULE | DAIKIN INDUSTRIES, LTD. (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230145113-A1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, MODULE AND COMPOUND | DAIKIN INDUSTRIES, LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230129817-A1 | ELECTROLYTE SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY AND MODULE | DAIKIN INDUSTRIES, LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-02-11 | — | — | US | disclosed |
| EP-2269611-B1 | EP2 and EP4 agonists as agents for the treatment of influenza A viral infection | GEMMUS PHARMA INC (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20150374715-A1 | EP2 AND EP4 AGONISTS AS AGENTS FOR THE TREATMENT OF INFLUENZA A VIRAL INFECTION | GEMMUS PHARMA INC (US) | 2015-12-31 | — | — | US | disclosed |
| US-8980944-B2 | EP2 and EP4 agonists as agents for the treatment of influenza a viral infection | GEMMUS PHARMA INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-4219479-A | STABILIZED PROSTACYCLINS, HYPOTENSIVE AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-08-26 | — | — | US | disclosed |
| US-4191694-A | HYPOTENSIVE, ANTISECRETORY, ANTIULCER, ANTIARRHYTHMIA AGENTS; ANTICOAGULANTS, DIURETICS | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-03-04 | — | — | US | disclosed |
| US-4159343-A | ABORTIFICANTS, LABOR INDUCTION, MENSTRUAL CYCLE REGULATION | SCHERING AKTIENGESELLSCHAFT (DE) | 1979-06-26 | — | — | US | disclosed |
| EP-0002234-A1 | New prostacyclin derivatives, their preparation and their use | SCHERING AKTIENGESELLSCHAFT (DE) | 1979-06-13 | — | — | EP | disclosed |
| US-4105792-A | OXYTOCICS, ABORTION INDUCTION | SCHERING AKTIENGESELLSCHAFT (DE) | 1978-08-08 | — | — | US | disclosed |
| US-4038410-A | ANTI-PROTOZOAN AGENTS | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-07-26 | — | — | US | disclosed |
| US-4011314-A | FOR TREATING ESTROGEN DEFICIENCY | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-03-08 | — | — | US | disclosed |
| US-3951958-A | VAGINOTROPIC | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
| US-3951959-A | VAGINOTROPIC | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374715-A1 | EP2 AND EP4 AGONISTS AS AGENTS FOR THE TREATMENT OF INFLUENZA A VIRAL INFECTION | PTGER4, PTGER2, PTGER1 | TAS2R14 2750/4885MMP3 1507/4885CA12 3161/4885 |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNJ2, KCNJ11 | TAS2R14 1880/4885MMP3 2716/4885CA12 2471/4885 |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | TAS2R14 1880/4885MMP3 2716/4885CA12 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.